Ardelyx Inc - Asset Resilience Ratio
Ardelyx Inc (ARDX) has an Asset Resilience Ratio of 41.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ARDX liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Ardelyx Inc's Asset Resilience Ratio has changed over time. See ARDX net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ardelyx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ARDX stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $199.99 Million | 41.14% |
| Total Liquid Assets | $199.99 Million | 41.14% |
Asset Resilience Insights
- Very High Liquidity: Ardelyx Inc maintains exceptional liquid asset reserves at 41.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Ardelyx Inc Industry Peers by Asset Resilience Ratio
Compare Ardelyx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Ardelyx Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Ardelyx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 42.49% | $185.17 Million | $435.75 Million | -12.22pp |
| 2023-12-31 | 54.72% | $162.83 Million | $297.58 Million | +40.11pp |
| 2022-12-31 | 14.61% | $27.77 Million | $190.07 Million | -14.91pp |
| 2021-12-31 | 29.52% | $44.26 Million | $149.91 Million | -17.83pp |
| 2020-12-31 | 47.36% | $95.45 Million | $201.56 Million | +21.80pp |
| 2019-12-31 | 25.55% | $66.38 Million | $259.78 Million | -23.17pp |
| 2018-12-31 | 48.72% | $89.32 Million | $183.33 Million | +11.61pp |
| 2017-12-31 | 37.11% | $58.59 Million | $157.90 Million | -22.12pp |
| 2016-12-31 | 59.22% | $126.22 Million | $213.13 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $116.95 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $113.41 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more